A pheochromocytoma is a tumor arising from chromaffin tissue in the adrenal medulla, whereas a paraganglioma is an extra-adrenal tumor of either the sympathetic or the parasympathetic chain, which ...

Patients diagnosed with pheochromocytoma or paraganglioma, tumors that form within certain endocrine tissues, such as the adrenal glands, may have abnormal endocrine activity due to the synthesis ...

The 2004 WHO classification of endocrine tumors defines pheochromocytoma as a tumor arising from catecholamine-producing chromaffin cells in the adrenal medulla -- an intra-adrenal paraganglioma.

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

MEN type 2B is a very rare disorder and can cause medullary thyroid cancer, pheochromocytoma, and lesions on the tongue and lips (mucosal neuromas). Familial paraganglioma-pheochromocytoma syndrome is ...

The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of May 26, 2025. “Pheochromocytoma and paraganglioma are rare tumours that form in and around the adrenal glands, and ...

1. Gruber LM, Erickson D, Babovic-Vuksanovic D, Thompson GB, Young Jr. WF, Bancos I: Pheochromocytoma and paraganglioma in patients with neurofibromatosis type 1. Clin Endocrinol (Oxf) 2017 ...

The expanded use would include treatment for patients aged 12 and older who suffer from advanced, unresectable or metastatic pheochromocytoma and paraganglioma, rare tumors that form in and around ...

The Rahway, N.J., drugmaker on Monday said the application covers Welireg for patients 12 years and older with advanced, unresectable or metastatic pheochromocytoma and paraganglioma. The FDA ...